Press Releases Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:52 2025-07-14 am EDT			5-day change	1st Jan Change
96.43 ^CHF	+0.21%		-1.72%	+8.71%

Jul. 14	Swiss Stocks Kick Start New Week Flat as Tariff Talks Weigh	MT
Jul. 14	August 1st Ultimatums and Other Summer Pastimes

Press Releases

Novartis receives approval for first malaria medicine for newborn babies and young infants	Jul. 08	GL
Novartis provides update on Phase III GCAptAIN study of Cosentyx in giant cell arteritis	Jul. 04	AQ
Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)	Jul. 03	GL
Novartis : Third Party Code v. 4.0	Jun. 30	PU
Novartis completes acquisition of Regulus Therapeutics	Jun. 25	GL
Novartis announces expiration of Regulus Therapeutics tender offer	Jun. 25	GL
Novartis announces expiration of HSR waiting period of Regulus Therapeutics tender offer	Jun. 23	GL
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNH	Jun. 12	GL
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer	Jun. 02	GL
Novartis Kisqali® reduces risk of recurrence in younger patients with early breast cancer in NATALEE subgroup analysis	Jun. 01	GL
Novartis announces commencement of tender offer to acquire Regulus Therapeutics	May. 27	GL
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline	May. 15	GL
Novartis : Earnings Document (novartis q1 2025 impact and sustainability update)	May. 05	PU
New $1.7b Novartis acquisition to advance novel microRNA inhibitor	May. 01	AQ
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure	Apr. 30	GL
Novartis: Q1 Earnings Snapshot	Apr. 29	AQ
Novartis : Earnings Document (novartis target patient populations 2025)	Apr. 29	PU
Novartis : Earnings Document (2025 04 interim financial report en)	Apr. 29	PU
Novartis : Earnings Document (q1 2025 investor presentation)	Apr. 29	PU
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1	Apr. 29	GL
Barbara Weber, M.D., Elected to ITM Supervisory Board	Apr. 10	AQ
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)	Apr. 02	GL
CD Milan, March 27, 2025, Procedural Order On Application To Intervene, UPC_CFI_698/2024	Apr. 02	AQ
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis	Mar. 31	GL
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer	Mar. 28	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

NOVARTIS : Q1 ahead of expectations; outlook revised higher

April 29, 2025 at 07:58 am EDT

Novartis CEO Says They Will Have to 'Tackle Rhetoric' in US Healthcare

January 21, 2025 at 03:33 pm EST

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT